Jimmy Carter Credits Merck's Keytruda For Cancer-Free Success

While Bristol-Myers Squibb & Co.'s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) is well ahead of Merck & Co.'s competing drug Keytruda (pembrolizumab) in FDA approved indications, it's the latter drug that's likely going to stick in the minds of the American public – at least for the time being.

While Bristol-Myers Squibb & Co.'s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) is well ahead of Merck & Co.'s competing drug Keytruda (pembrolizumab) in FDA approved indications, it's the latter drug that's likely going to stick in the minds of the American public – at least for the time being.

Former US President Jimmy Carter, who was diagnosed in August with metastatic melanoma that had spread to his brain, said...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By 

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.